, Volume 117, Issue 7, pp 855-859,
Open Access This content is freely available online to anyone, anywhere at any time.

Transdermal rotigotine for the perioperative management of Parkinson’s disease

Abstract

Continuous delivery of antiparkinsonian medication during a perioperative period is desirable to avoid ‘off’-symptom complications in surgical patients with concomitant Parkinson’s disease (PD). Fourteen PD patients undergoing surgery under general anesthesia were switched from oral dopaminergic medication to transdermally delivered 24-h rotigotine (median dose 12 mg/24 h) for the perioperative period. Rotigotine treatment was considered feasible by patients, their anesthesiologists and neurologists with good control of PD symptoms and easy switching and re-switching of PD medication.

For the NEUPOS Study Group.